作者更正：沙库巴曲缬沙坦对心力衰竭患者植入式除颤器资格的影响：真实世界经验。
Author Correction: Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
机构信息
Department of Cardiology, Policlinico Casilino, Rome, Italy.
出版信息
Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2216. doi: 10.26355/eurrev_202204_28446.
Correction to: European Review for Medical and Pharmacological Sciences 2021; 25 (18): 5690-5700-DOI: 10.26355/eurrev_202109_26788-PMID: 34604961, published online on 30 September 2021. After publication, the authors applied to change the first two lines of Table II as the second column results were erroneously shifted in the first column. In this way, the results were quite difficult to understand. There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/26788.
更正
《欧洲医学与药物科学评论》2021 年；25（18）：5690-5700-DOI：10.26355/eurrev_202109_26788-PMID：34604961，在线发表于 2021 年 9 月 30 日。发表后，作者申请更改表 II 的前两行，因为第一列的第二列结果错误移位。这样，结果就很难理解。本文有修订。出版商对由此造成的任何不便表示歉意。https://www.europeanreview.org/article/26788.
Zotero 插件